Nine fasting patients (seven men, two women), whose mean age was 41 years (range=24 to 67 years), had blood drawn for plasma lipid panels and their weight measured before starting treatment with olanzapine. This information was obtained by means of routine hospital data collection; therefore, written informed consent was not obtained. The panels consisted of cholesterol, triglyceride, and high- and low-density lipoprotein levels. Lipid panel results and patients’ weights were reexamined after an average of 16 months of treatment. The patients’ mean dose of olanzapine was 19 mg/day (range=10 to 30). Patients also received adjunctive treatments, with mood stabilizers most often prescribed.